<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25032217</article-id><article-id pub-id-type="pmc">4086227</article-id><article-id pub-id-type="doi">10.1155/2014/591867</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in <italic>KRAS</italic> Wild-Type Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Er</surname><given-names>Tze-Kiong</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3847-3690</contrib-id><name><surname>Chen</surname><given-names>Chih-Chieh</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bujanda</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6905-0693</contrib-id><name><surname>Herreros-Villanueva</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Molecular Diagnostics, Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan</aff><aff id="I2"><sup>2</sup>Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan</aff><aff id="I3"><sup>3</sup>Center for Lipid Biosciences, Kaohsiung Medical University Hospital, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan</aff><aff id="I4"><sup>4</sup>Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, No. 195, Section 4, Chung-Hsing Road, Chutung, Hsinchu 31040, Taiwan</aff><aff id="I5"><sup>5</sup>Department of Gastroenterology, Donostia Hospital, Biodonostia Institute, Center for Biomedical Research in Network for Hepatic and Digestives Diseases (CIBERehd), Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Enfermedades Hep&#x000e1;ticas y Digestivas (CIBERehd), University of Basque Country, 20014 San Sebastian, Spain</aff><author-notes><corresp id="cor1">*Marta Herreros-Villanueva: <email>martahvh1978@hotmail.com</email></corresp><fn fn-type="other"><p>Academic Editor: Mina Hur</p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>591867</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Tze-Kiong Er et al.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Targeting epidermal growth factor receptor (EGFR) has been one of the most effective colorectal cancer strategies. Anti-EGFR antibodies function by binding to the extracellular domain of EGFR, preventing its activation, and ultimately providing clinical benefit. <italic>KRAS</italic> mutations in codons 12 and 13 are recognized prognostic and predictive biomarkers that should be analyzed at the clinic prior to the administration of anti-EGFR therapy. However, still an important fraction of <italic>KRAS</italic> wild-type patients do not respond to the treatment. The identification of additional genetic determinants of primary or secondary resistance to EGFR targeted therapy for further improving the selection of patients is urgent. Herein, we review the latest published literature highlighting the most important genes that may predict resistance to anti-EGFR monoclonal antibodies in colorectal cancer patients. According to the available findings, the evaluation of <italic>BRAF</italic>, <italic>NRAS</italic>, <italic>PIK3CA</italic>, and <italic>PTEN</italic> status could be the right strategy to select patients who are likely to respond to anti-EGFR therapies. In the future, the combination of those biomarkers will help establish consensus that can be introduced into clinical practice.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>With a global increasing incidence of more than one million cases annually and status as the third most common cancer, colorectal cancer (CRC) is a major health burden [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. Important progress has been made in the treatment of this disease since the introduction of new therapies that have improved patient survival even after metastasis development. Targeting epidermal growth factor receptor (EGFR) has been intensively pursued as a cancer strategy. In the clinical setting of CRC, the use of monoclonal antibodies to block EGFR has demonstrated important clinical benefit exhibiting antitumor activity as monotherapy or in combination with chemotherapy and/or radiation. In particular, the antibodies cetuximab (IMC-C225, Erbitux) and panitumumab (Vectibix) work by binding to the extracellular domain of EGFR and preventing its activation. Mechanistically, both antibodies prevent EGFR receptor activation and dimerization and ultimately induce receptor internalization and downregulation [<xref rid="B3" ref-type="bibr">3</xref>].</p></sec><sec id="sec2"><title>2. Structure of KRAS, NRAS, BRAF, and PIK3CA Proteins</title><p>
<italic>KRAS</italic>,<italic> NRAS</italic>, or<italic> BRAF</italic> mutations can all activate the RAS-RAF-MAPK pathway, which is downstream from EGFR. The KRAS and NRAS hotspot mutation sites G12, G13, Q61, and A146 are indicated in Figures <xref ref-type="fig" rid="fig1">1(a)</xref> and <xref ref-type="fig" rid="fig1">1(b)</xref> showing as the red spheres. These mutations activate the oncogenic properties of RAS proteins and it has been reported that they do so by inhibiting GTPase activity. The BRAF hotspot mutation, V600E, located at the A-loop is highlighted in red spheres (<xref ref-type="fig" rid="fig1">Figure 1(c)</xref>). This mutation may disrupt an inactive conformation of BRAF kinase. Therefore,<italic> BRAF</italic> V600E increases the kinase activity that provides cancer cells with both proliferation and survival signals and promotes them to become tumors in the model system.<italic> PIK3CA</italic> mutations activate the PI3&#x02009;K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. The PIK3CA mutations E545 and H1047 are located at the helical domain and kinase domain of the protein, respectively (<xref ref-type="fig" rid="fig1">Figure 1(d)</xref>). Studies showed that mutant E545 inhibits the activity of the catalytic subunit, because it interacts with L379 and A340 of the p85 nSH2 domain. The mutant H1047 has a direct effect on the conformation of the activation loop, changing its interaction with phosphatidylinositol substrates. Notably, Smith et al. [<xref rid="B4" ref-type="bibr">4</xref>] found that exon 9, but not exon 20, mutations in<italic> PIK3CA</italic> were associated with<italic> KRAS</italic> mutations. Exon 9 mutations lie in the helical domain of protein and require interaction with GTP bound RAS. Moreover, exon 20 mutations lie in the kinase domain and require p85 binding but are independent of GTP bound RAS [<xref rid="B5" ref-type="bibr">5</xref>].</p></sec><sec id="sec3"><title>3. Potential Biomarkers for Anti-EGFR Therapy</title><sec id="sec3.1"><title>3.1. KRAS</title><p>It is well known that<italic> KRAS</italic> mutation is the first described and most important factor contributing to anti-EGFR therapies [<xref rid="B6" ref-type="bibr">6</xref>].<italic> KRAS</italic> mutations have been reported to be associated with a lack of response to cetuximab and panitumumab and/or poorer survival in chemorefractory metastatic CRC patients in several independent studies [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref>]. The hypothesis is that<italic> KRAS</italic> mutation activates the RAS/MAPK signaling pathway downstream of EGFR independently of ligand binding to the receptor. Based on confirmed preclinical and clinical data, the European Medicines Agency and the U.S. Food and Drug Administration (FDA) have suggested that only<italic> KRAS</italic> wild-type patients should be candidates to receive cetuximab or panitumumab.</p><p>Although 40&#x02013;60% of CRCs are<italic> KRAS</italic> wild-type [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>], the response rate to cetuximab in monotherapy is approximately 10% and does not exceed 23% even when combined with chemotherapy. A very recent hypothesis suggested that<italic> KRAS</italic> mutations may not be detected in initial disease because a small number of cells with<italic> KRAS</italic> mutations exist in the presence of a vast majority of wild-type<italic> KRAS</italic> cells. Diaz et al. found that 38% of patients whose tumors were initially<italic> KRAS</italic> wild-type developed<italic> KRAS</italic> mutations that were detectable in their sera after 5-6 months of treatment [<xref rid="B12" ref-type="bibr">12</xref>]. Recently, Custodio and Feliu indicated that, in addition to<italic> KRAS</italic>, there are signaling events/molecules downstream of EGFR that can become unregulated [<xref rid="B13" ref-type="bibr">13</xref>]. It is therefore necessary to identify the factors that contribute to anti-EGFR resistance in<italic> KRAS</italic> wild-type patients.</p></sec><sec id="sec3.2"><title>3.2. BRAF</title><p>The detection of<italic> BRAF</italic> mutations is currently included in some clinical laboratory protocols, although it has not been established as routine clinical practice. BRAF is a protein member of the<italic> RAF</italic> family (RAF1, BRAF, ARAF), also regulated by RAS binding.</p><p>
<italic>BRAF</italic> encodes a serine-threonine protein kinase that is the most important downstream effector of activated KRAS [<xref rid="B14" ref-type="bibr">14</xref>]. Mutated BRAF activates a signaling cascade involving proteins in the mitogen-activated protein kinase system, resulting in cell proliferation [<xref rid="B15" ref-type="bibr">15</xref>]. Approximately 15% of CRCs have the<italic> BRAF</italic> mutation, and this is an indicator of poor prognosis regardless of the treatment or administration [<xref rid="B16" ref-type="bibr">16</xref>]. Most of the<italic> BRAF</italic> mutations associated with cancer are located in exons 11 and 15, coding for the kinase domain. The hotspot mutation is the T-to-A transversion at nucleotide 1796 that corresponds to the V600E mutation. This mutation is predisposed to the inhibition of apoptosis and also aids in increasing invasiveness [<xref rid="B17" ref-type="bibr">17</xref>]. It has also been suggested that<italic> BRAF</italic> mutation is a negative prognostic indicator in CRC [<xref rid="B18" ref-type="bibr">18</xref>] and a negative predictor of response to EGFR inhibitors, according to results from CRYSTAL, OPUS, and PICCOLO trials [<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>].<italic> BRAF</italic> mutation was also associated with shorter progression-free survival (PFS) and overall survival (OS) [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>].<italic> KRAS</italic> and<italic> BRAF</italic> mutations are mutually exclusive in CRC [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]; therefore, the National Comprehensive Cancer Network (NCCN) suggests considering<italic> BRAF</italic> mutation testing when<italic> KRAS</italic> is wild-type [<xref rid="B26" ref-type="bibr">26</xref>]. Different studies demonstrated that<italic> BRAF</italic> mutation confers resistance to both cetuximab and panitumumab [<xref rid="B25" ref-type="bibr">25</xref>]. Specifically,<italic> BRAF</italic> is responsible for resistance when patients received anti-EGFR therapy in a second or subsequent round of treatment, as shown in several retrospective studies [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>]. In contrast, the predictive value of<italic> BRAF</italic> mutations in first line treatment has not been fully demonstrated [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>]. A recent study conducted by Saridaki et al. showed lower PFS and OS in BRAF V600E mutated patients compared with wild-type (4.2 versus 11.1 months and 14.3 versus 35.0 months, resp.), although differences were not significantly significant [<xref rid="B31" ref-type="bibr">31</xref>]. Due to the poor prognosis of<italic> BRAF</italic> mutated patients and the lack of response to anti-EGFR therapy, rational therapeutic strategies have been directed toward selective RAF inhibitors. For instance, BRAF inhibitors used for melanoma have also been tested against CRC. However, very little clinical benefit was observed, suggesting that the biological behavior in melanoma and colorectal cancer can be different.</p></sec><sec id="sec3.3"><title>3.3. NRAS</title><p>KRAS and NRAS are highly homologous and closely related to KRAS [<xref rid="B32" ref-type="bibr">32</xref>]. Mutant<italic> NRAS</italic> has been reported to have an antiapoptotic function and promotes CRC in an inflammatory context [<xref rid="B33" ref-type="bibr">33</xref>]. Unlike<italic> KRAS</italic> mutations, which are commonly seen in CRC,<italic> NRAS</italic> mutations are found in approximately 3&#x02013;5% of CRCs and occur most commonly in codon 61 rather than in codon 12 or 13 [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B34" ref-type="bibr">34</xref>].<italic> NRAS</italic> mutations like<italic> BRAF</italic> mutations are mutually exclusive from<italic> KRAS</italic> mutations [<xref rid="B26" ref-type="bibr">26</xref>]. Because<italic> KRAS</italic> and<italic> NRAS</italic> mutations are mutually exclusive,<italic> NRAS</italic> mutation testing should be performed when<italic> KRAS</italic> is wild-type. To date, several studies demonstrated that the presence of<italic> NRAS</italic> mutations is associated with a lack of response to cetuximab therapy [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B24" ref-type="bibr">24</xref>]. Shen et al. showed that 4.19% (26/621) of tumors harbored an<italic> NRAS</italic> mutation and distant metastatic tumors had a higher<italic> NRAS</italic> mutation rate [<xref rid="B34" ref-type="bibr">34</xref>]. The authors recommended that<italic> NRAS</italic> mutation detection should be considered before anti-EGFR therapy, especially in<italic> KRAS</italic> wild-type tumors. Recently, Russo et al. found that<italic> NRAS</italic> mutations were identified almost exclusively in patients with rectal cancer and were more common in older patients [<xref rid="B35" ref-type="bibr">35</xref>]. They also showed that<italic> NRAS</italic> mutation was not associated with clinical outcomes. However, di Bartolomeo et al. indicated that<italic> KRAS</italic>/<italic>NRAS</italic> wild-type status was the most important predictor of efficacy in terms of PFS in a TEGAFOX-E (cetuximab, oxaliplatin, and oral uracil/ftorafur-UFT) phase II study [<xref rid="B36" ref-type="bibr">36</xref>]. Additionally, Douillard et al. reported that additional<italic> RAS</italic> mutations predicted a lack of response in patients with mCRC who received panitumumab-FOLFOX4 [<xref rid="B37" ref-type="bibr">37</xref>]. Most recently, Sclafani et al. showed that a significant proportion of<italic> KRAS</italic>/<italic>BRAF</italic> wild-type patients (17%) had<italic> RAS</italic> mutations beyond<italic> KRAS</italic> exons 2-3 (additional<italic> KRAS</italic> mutations in 10.2%,<italic> NRAS</italic> mutations in 6.8%) in retrospective analysis (EXPERT-C trial) [<xref rid="B38" ref-type="bibr">38</xref>]. They also found that the addition of cetuximab was associated with higher response; however, this was not statistically significant. Based on the published literature,<italic> NRAS</italic> mutation testing is required before initiating treatment with EGFR inhibitors. Notably, the Medicines and Healthcare Products Regulatory Agency (MHRA) indicates that the evidence of wild-type RAS status (at exons 2, 3, and 4 of KRAS and NRAS) is required before initiating treatment with panitumumab alone or in combination with other chemotherapy for metastatic colorectal cancer (mCRC). Genetic testing for<italic> RAS</italic> gene mutations (in<italic> KRAS</italic> and<italic> NRAS</italic>) beyond the routine analysis of<italic> KRAS</italic> exon 2 will become the standard for selecting patients for anti-EGFR therapy in near future.</p></sec><sec id="sec3.4"><title>3.4. PI3&#x02009;K/PTEN/AKT</title><p>Several preclinical studies note the importance of the PI3&#x02009;K/PTEN/AKT pathway in determining the sensitivity of CRC cell lines to cetuximab.<italic> PI3KCA</italic> mutations, present in 10&#x02013;25% of CRCs [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B39" ref-type="bibr">39</xref>&#x02013;<xref rid="B41" ref-type="bibr">41</xref>], have been reported to be &#x0201c;gain of function&#x0201d; mutations activating the PI3&#x02009;K/AKT pathway.<italic> PIK3CA</italic> mutations, which are located in exon 9 or exon 20, can coincide with<italic> KRAS</italic> and<italic> BRAF</italic> mutations [<xref rid="B42" ref-type="bibr">42</xref>] and exert different oncogenic effects including resistance to anti-EGFR therapies. Although the role of the<italic> PIK3CA</italic> mutational status in the anti-EGFR response is still controversial, several published studies agree on the fact that there is a significant negative correlation between<italic> PIK3CA</italic> mutation in codon 20 and the response to anti-EGFR antibodies [<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B43" ref-type="bibr">43</xref>]. In contrast, Prenen et al. [<xref rid="B41" ref-type="bibr">41</xref>] did not find this association, and Karapetis et al. concluded that, in chemotherapy-refractory colorectal cancer, neither<italic> PIK3CA</italic> mutation status nor PTEN expression was prognostic, or predictive of benefit from cetuximab [<xref rid="B44" ref-type="bibr">44</xref>]. Additionally, recent data suggest that<italic> PIK3CA</italic> exon 20 mutations are associated with poorer PFS, OS, and objective response to anti-EGFR antibodies, whereas patients with mutations in codon 9 are equally responsive to wild-type subjects [<xref rid="B45" ref-type="bibr">45</xref>]. Taking these data together, we can conclude that most published literature supports a role of<italic> PIK3CA</italic> exon 20 in predicting resistance to cetuximab and panitumumab, but further studies need to be performed to display clinical significance.</p><p>PTEN is a key tumor suppressor gene involved in PI3&#x02009;K/AKT signaling. The loss of PTEN, by mutation, allelic loss, or epigenetic events results in the persistent activation of PI3K effectors [<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>]. It has been shown that the loss of PTEN is present in 19&#x02013;42% of CRCs and often coincides with<italic> KRAS</italic>,<italic> BRAF</italic>, and<italic> PI3KCA</italic> mutations [<xref rid="B48" ref-type="bibr">48</xref>]. Preclinical data have shown that PTEN loss confers resistance to cetuximab-induced apoptosis in CRC cell lines [<xref rid="B49" ref-type="bibr">49</xref>]. Jhawer et al. [<xref rid="B49" ref-type="bibr">49</xref>] also demonstrated that<italic> PI3KCA</italic> mutation and PTEN expression predict a poor response of colon cancer cells to cetuximab. Some groups suggested that the loss of PTEN protein expression is associated with nonresponsiveness to cetuximab [<xref rid="B50" ref-type="bibr">50</xref>]. Retrospective studies provided evidence that the loss of PTEN is associated with poorer response to cetuximab [<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>]. In contrast, Razis et al. did not find association between PTEN protein expression and clinical outcomes in patients treated with cetuximab [<xref rid="B52" ref-type="bibr">52</xref>]. However, because there are contradictory results, principally due to protein expression interpretation, further prospective studies are needed to evaluate PTEN expression for its use in the clinical setting.</p><p>Although AKT phosphorylation has been correlated with the response to gefitinib [<xref rid="B53" ref-type="bibr">53</xref>], its association with the response to cetuximab has not been addressed. In contrast, some reports have shown that p-AKT can modulate the response to anti-EGFR antibodies [<xref rid="B54" ref-type="bibr">54</xref>]. In conclusion, there is no clear evidence useful to the clinical setting to support an improved response to anti-EGFR therapies based on AKT phosphorylation.</p></sec><sec id="sec3.5"><title>3.5. HER Family Members</title><p>Different preclinical data have suggested that the heterodimers of EGFR with other members of the HER family, such as HER2 and HER3, may affect anti-EGFR therapies. Wheeler et al. [<xref rid="B55" ref-type="bibr">55</xref>] analyzed resistance in lung cancer and observed that EGFR, HER2, HER3, and c-MET were highly activated in cetuximab-resistant clones derived from lung cancer cell lines. Their data demonstrated the dysregulation of EGFR internalization/degradation and the subsequent EGFR-dependent activation of HER2 and HER3. Furthermore, it appears that HER3 activity, which depends on EGFR and HER2, represents a critical step for cells to overcome cetuximab effects. Additionally, c-MET was highly phosphorylated in the absence of its ligand HGF. A recent paper has shown that the amplification of the MET protooncogene is associated with<italic> de novo</italic> and acquired resistance in wild-type tumors [<xref rid="B56" ref-type="bibr">56</xref>].</p><p>Large-scale retrospective analyses have been performed to strengthen the role of HER2 as a resistance biomarker in CRC. The frequency of HER2 amplification is similar to other genes such as BRAF and NRAS [<xref rid="B42" ref-type="bibr">42</xref>], and the evaluation of the HER2 gene by FISH may in fact be an additional useful test for the identification of mCRC patients who will benefit from anti-EGFR targeted therapies. Martin et al. [<xref rid="B57" ref-type="bibr">57</xref>] concluded that patients with an increased HER2 gene copy number show a worse response to anti-EGFR antibodies. In addition, a phase I clinical trial demonstrated that anti-HER2 therapy combined with cetuximab in refractory CRC was associated with antitumor activity, although the combination was not tolerable due to overlapping toxicities [<xref rid="B58" ref-type="bibr">58</xref>]. However, HER2 testing needs to be further investigated for future personalized medicine.</p></sec><sec id="sec3.6"><title>3.6. MicroRNAs</title><p>MicroRNA (miRNAs) are a class of endogenous, short (17&#x02013;25 nucleotides), noncoding single-stranded RNAs involved in the posttranscriptional regulation of gene expression [<xref rid="B59" ref-type="bibr">59</xref>]. miRNA causes either the degradation or the inhibition of translation by binding imperfectly to the 3&#x02032;-untranslated region of targeted mRNA [<xref rid="B60" ref-type="bibr">60</xref>]. Dysregulated miRNAs are associated with CRC development, progression, and therapeutic response [<xref rid="B61" ref-type="bibr">61</xref>]. Ragusa et al. demonstrated that the downregulation of members of the Let-7 family was a predictive marker of cetuximab sensitivity [<xref rid="B62" ref-type="bibr">62</xref>]. They also showed that miR-146b-3p and miR-486-5p were less abundant in<italic> KRAS</italic> wild-type compared with<italic> KRAS</italic>-mutated tumors. Similarly, two studies implicated the potential role of Let-7 family members in<italic> KRAS</italic> regulation and anti-EGFR therapy sensitivity in CRC [<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>]. Additionally, Sebio et al. showed a LCS6 polymorphism in the 3&#x02032;-UTR of KRAS, which is in a binding site for Let-7, may serve as a predictive marker of anti-EGFR treatment in<italic> KRAS</italic> wild-type and<italic> BRAF</italic> wild-type patients [<xref rid="B65" ref-type="bibr">65</xref>]. Meanwhile, Pichler et al. showed that low expression of miR-200a is associated with poor survival [<xref rid="B66" ref-type="bibr">66</xref>]. Furthermore, Cappuzzo et al. showed that patients highly expressing the miR-99a/Let-7c/miR-125b cluster showed longer PFS and longer OS than patients expressing low levels of the cluster in the<italic> KRAS</italic> wild-type population [<xref rid="B61" ref-type="bibr">61</xref>]. They thus concluded that the miR-99a/Let-7c/miR-125b signature may improve the selection of<italic> KRAS</italic> wild-type patients for anti-EGFR therapy. Recently, Pichler et al. indicated that the miR-181a expression level is associated with poor survival in patients with CRC and that miR-181a expression may predict PFS in EGFR targeted therapy [<xref rid="B67" ref-type="bibr">67</xref>]. Based on these findings, miRNAs could be used as predictive biomarkers in selecting patients for anti-<italic>EGFR</italic> antibody therapy in the future.</p></sec></sec><sec id="sec4"><title>4. Conclusion</title><p>According to the available data obtained during the last decade, it is clear that the evaluation of not only the<italic> KRAS</italic> mutational status but also<italic> BRAF</italic>,<italic> NRAS</italic>,<italic> PIK3CA</italic>, and<italic> PTEN</italic> alterations could be beneficial to the selection of patients who are likely to respond to anti-EGFR therapies (<xref ref-type="fig" rid="fig2">Figure 2</xref>). However, there are no guidelines or recommendations from the European group, United States-based group, or Canadian Expert group recommending the use of<italic> BRAF</italic>,<italic> NRAS</italic>,<italic> PIK3CA</italic>, PTEN, or AKT to select CRC patient for anti-EGFR antibody therapy [<xref rid="B68" ref-type="bibr">68</xref>]. Notably, the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (EWG) found insufficient evidence to recommend or discourage testing for mutations in BRAF V600E, NRAS, or PIK3CA and/or loss of PTEN or AKT protein. Therefore, the EWG discourages the use of these tests for deciding whether to introduce anti-EGFR therapy with cetuximab or panitumumab until more evidence supports improved clinical outcomes [<xref rid="B69" ref-type="bibr">69</xref>]. Moreover, a meta-analysis suggests that mutations in<italic> KRAS</italic> exons 3 and 4,<italic> NRAS</italic>,<italic> BRAF</italic>,<italic> PIK3CA</italic>, and nonfunctional PTEN predict resistance to anti-EGFR therapies [<xref rid="B70" ref-type="bibr">70</xref>] and concluded that these biomarkers should be implemented for prediction of clinical benefit from anti-EGFR antibodies in mCRC.</p><p>In the near future, a panel of multiple genes is likely to be analyzed simultaneously and used for selecting patients and predicting the efficacy of anti-EGFR therapy (<xref ref-type="fig" rid="fig3">Figure 3</xref>). A panel of these different mutations identifies a subgroup of mCRC patients with distinct biological behavior and response to treatments, including anti-EGFR antibodies. This panel will be a step forward in the &#x0201c;personalized medicine&#x0201d; treatment of CRC patients. In summary, the main molecular markers described in this review may enable an accurate selection of patients who will benefit from anti-EGFR therapy.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by Grants from Kaohsiung Medical University Hospital (KMUH102-M207) and Ministry of Health and Welfare (MOHW103-TD-B-111-05). Marta Herreros-Villanueva is supported by Universidad del Pais Vasco, Instituto Biodonostia, San Sebastian, and CIBERehd (Red de Enfermedades Hepaticas y Digestivas).</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><sec><title>Authors' Contribution</title><p>Tze-Kiong Er and Chih-Chieh Chen contributed equally to this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Desantis</surname><given-names>C</given-names></name><name><surname>Virgo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cancer treatment and survivorship statistics, 2012</article-title><source><italic>CA: A Cancer Journal for Clinicians</italic></source><year>2012</year><volume>62</volume><issue>4</issue><fpage>220</fpage><lpage>241</lpage><pub-id pub-id-type="other">2-s2.0-84863707351</pub-id><pub-id pub-id-type="pmid">22700443</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther</surname><given-names>A</given-names></name><name><surname>Johnstone</surname><given-names>E</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><name><surname>Midgley</surname><given-names>R</given-names></name><name><surname>Tomlinson</surname><given-names>I</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name></person-group><article-title>Genetic prognostic and predictive markers in colorectal cancer</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2009</year><volume>9</volume><issue>7</issue><fpage>489</fpage><lpage>499</lpage><pub-id pub-id-type="other">2-s2.0-67649506174</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunada</surname><given-names>H</given-names></name><name><surname>Magun</surname><given-names>BE</given-names></name><name><surname>Mendelsohn</surname><given-names>J</given-names></name><name><surname>MacLeod</surname><given-names>CL</given-names></name></person-group><article-title>Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1986</year><volume>83</volume><issue>11</issue><fpage>3825</fpage><lpage>3829</lpage><pub-id pub-id-type="other">2-s2.0-0008486660</pub-id><pub-id pub-id-type="pmid">2424012</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CG</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Claes</surname><given-names>B</given-names></name><etal/></person-group><article-title>Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy &#x000b1; cetuximab</article-title><source><italic>Clinical Cancer Research</italic></source><year>2013</year><volume>19</volume><issue>15</issue><fpage>4104</fpage><lpage>4113</lpage><pub-id pub-id-type="other">2-s2.0-84881255039</pub-id><pub-id pub-id-type="pmid">23741067</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name></person-group><article-title>Helical domain and kinase domain mutations in p110<italic>&#x003b1;</italic> of phosphatidylinositol 3-kinase induce gain of function by different mechanisms</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2008</year><volume>105</volume><issue>7</issue><fpage>2652</fpage><lpage>2657</lpage><pub-id pub-id-type="other">2-s2.0-40649096375</pub-id><pub-id pub-id-type="pmid">18268322</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amado</surname><given-names>RG</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><etal/></person-group><article-title>Wild-type <italic>KRAS</italic> is required for panitumumab efficacy in patients with metastatic colorectal cancer</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2008</year><volume>26</volume><issue>10</issue><fpage>1626</fpage><lpage>1634</lpage><pub-id pub-id-type="other">2-s2.0-42649145667</pub-id><pub-id pub-id-type="pmid">18316791</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Roock</surname><given-names>W</given-names></name><name><surname>Piessevaux</surname><given-names>H</given-names></name><name><surname>de Schutter</surname><given-names>J</given-names></name><etal/></person-group><article-title>
<italic>KRAS</italic> wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab</article-title><source><italic>Annals of Oncology</italic></source><year>2008</year><volume>19</volume><issue>3</issue><fpage>508</fpage><lpage>515</lpage><pub-id pub-id-type="other">2-s2.0-40149088765</pub-id><pub-id pub-id-type="pmid">17998284</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>di Fiore</surname><given-names>F</given-names></name><name><surname>Blanchard</surname><given-names>F</given-names></name><name><surname>Charbonnier</surname><given-names>F</given-names></name><etal/></person-group><article-title>Clinical relevance of <italic>KRAS</italic> mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy</article-title><source><italic>British Journal of Cancer</italic></source><year>2007</year><volume>96</volume><issue>8</issue><fpage>1166</fpage><lpage>1169</lpage><pub-id pub-id-type="other">2-s2.0-34247278727</pub-id><pub-id pub-id-type="pmid">17375050</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li&#x000e8;vre</surname><given-names>A</given-names></name><name><surname>Bachet</surname><given-names>J-B</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><etal/></person-group><article-title>
<italic>KRAS</italic> mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2008</year><volume>26</volume><issue>3</issue><fpage>374</fpage><lpage>379</lpage><pub-id pub-id-type="other">2-s2.0-38649099966</pub-id><pub-id pub-id-type="pmid">18202412</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herreros-Villanueva</surname><given-names>M</given-names></name><name><surname>Rodrigo</surname><given-names>M</given-names></name><name><surname>Claver</surname><given-names>M</given-names></name><etal/></person-group><article-title>
<italic>KRAS</italic>, <italic>BRAF</italic>, <italic>EGFR</italic> and <italic>HER2</italic> gene status in a Spanish population of colorectal cancer</article-title><source><italic>Molecular Biology Reports</italic></source><year>2011</year><volume>38</volume><issue>2</issue><fpage>1315</fpage><lpage>1320</lpage><pub-id pub-id-type="other">2-s2.0-79951578834</pub-id><pub-id pub-id-type="pmid">20563851</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karapetis</surname><given-names>CS</given-names></name><name><surname>Khambata-Ford</surname><given-names>S</given-names></name><name><surname>Jonker</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>K-ras mutations and benefit from cetuximab in advanced colorectal cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2008</year><volume>359</volume><issue>17</issue><fpage>1757</fpage><lpage>1765</lpage><pub-id pub-id-type="other">2-s2.0-54949085398</pub-id><pub-id pub-id-type="pmid">18946061</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>LA</given-names><suffix>Jr.</suffix></name><name><surname>Williams</surname><given-names>RT</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>The molecular evolution of acquired resistance to targeted <italic>EGFR</italic> blockade in colorectal cancers</article-title><source><italic>Nature</italic></source><year>2012</year><volume>486</volume><issue>7404</issue><fpage>537</fpage><lpage>540</lpage><pub-id pub-id-type="other">2-s2.0-84863000299</pub-id><pub-id pub-id-type="pmid">22722843</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Custodio</surname><given-names>A</given-names></name><name><surname>Feliu</surname><given-names>J</given-names></name></person-group><article-title>Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond <italic>KRAS</italic> mutations</article-title><source><italic>Critical Reviews in Oncology/Hematology</italic></source><year>2013</year><volume>85</volume><issue>1</issue><fpage>45</fpage><lpage>81</lpage><pub-id pub-id-type="other">2-s2.0-84870812342</pub-id><pub-id pub-id-type="pmid">22647972</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajagopalan</surname><given-names>H</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name></person-group><article-title>
<italic>RAF/RAS</italic> oncogenes and mismatch-repair status</article-title><source><italic>Nature</italic></source><year>2002</year><volume>418</volume><issue>6901</issue><fpage>p. 934</fpage><pub-id pub-id-type="other">2-s2.0-0037194728</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolch</surname><given-names>W</given-names></name></person-group><article-title>Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions</article-title><source><italic>Biochemical Journal</italic></source><year>2000</year><volume>351</volume><issue>2</issue><fpage>289</fpage><lpage>305</lpage><pub-id pub-id-type="other">2-s2.0-0034667593</pub-id><pub-id pub-id-type="pmid">11023813</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Tejpar</surname><given-names>S</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic role of <italic>KRAS</italic> and <italic>BRAF</italic> in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2010</year><volume>28</volume><issue>3</issue><fpage>466</fpage><lpage>474</lpage><pub-id pub-id-type="other">2-s2.0-75749102647</pub-id><pub-id pub-id-type="pmid">20008640</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minoo</surname><given-names>P</given-names></name><name><surname>Moyer</surname><given-names>MP</given-names></name><name><surname>Jass</surname><given-names>JR</given-names></name></person-group><article-title>Role of <italic>BRAF</italic>-V600E in the serrated pathway of colorectal tumourigenesis</article-title><source><italic>Journal of Pathology</italic></source><year>2007</year><volume>212</volume><issue>2</issue><fpage>124</fpage><lpage>133</lpage><pub-id pub-id-type="other">2-s2.0-34249785078</pub-id><pub-id pub-id-type="pmid">17427169</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Cutsem</surname><given-names>E</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>C-H</given-names></name><name><surname>L&#x000e1;ng</surname><given-names>I</given-names></name><etal/></person-group><article-title>Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor <italic>KRAS</italic> and <italic>BRAF</italic> mutation status</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2011</year><volume>29</volume><issue>15</issue><fpage>2011</fpage><lpage>2019</lpage><pub-id pub-id-type="other">2-s2.0-79956298812</pub-id><pub-id pub-id-type="pmid">21502544</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Cutsem</surname><given-names>E</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>C-H</given-names></name><name><surname>Hitre</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2009</year><volume>360</volume><issue>14</issue><fpage>1408</fpage><lpage>1417</lpage><pub-id pub-id-type="other">2-s2.0-63849088630</pub-id><pub-id pub-id-type="pmid">19339720</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study</article-title><source><italic>Annals of Oncology</italic></source><year>2011</year><volume>22</volume><issue>7</issue><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="other">2-s2.0-79956310674</pub-id><pub-id pub-id-type="pmid">21228335</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seymour</surname><given-names>MT</given-names></name><name><surname>Brown</surname><given-names>SR</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><etal/></person-group><article-title>Panitumumab and irinotecan versus irinotecan alone for patients with <italic>KRAS</italic> wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial</article-title><source><italic>The Lancet Oncology</italic></source><year>2013</year><volume>14</volume><issue>8</issue><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="other">2-s2.0-84879786289</pub-id><pub-id pub-id-type="pmid">23725851</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loupakis</surname><given-names>F</given-names></name><name><surname>Ruzzo</surname><given-names>A</given-names></name><name><surname>Cremolini</surname><given-names>C</given-names></name><etal/></person-group><article-title>
<italic>KRAS</italic> codon 61, 146 and <italic>BRAF</italic> mutations predict resistance to cetuximab plus irinotecan in <italic>KRAS</italic> codon 12 and 13 wild-type metastatic colorectal cancer</article-title><source><italic>British Journal of Cancer</italic></source><year>2009</year><volume>101</volume><issue>4</issue><fpage>715</fpage><lpage>721</lpage><pub-id pub-id-type="other">2-s2.0-68749119351</pub-id><pub-id pub-id-type="pmid">19603018</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maughan</surname><given-names>TS</given-names></name><name><surname>Adams</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial</article-title><source><italic>The Lancet</italic></source><year>2011</year><volume>377</volume><issue>9783</issue><fpage>2103</fpage><lpage>2114</lpage><pub-id pub-id-type="other">2-s2.0-79959337678</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Roock</surname><given-names>W</given-names></name><name><surname>Claes</surname><given-names>B</given-names></name><name><surname>Bernasconi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of <italic>KRAS</italic>, <italic>BRAF</italic>, <italic>NRAS</italic>, and <italic>PIK3CA</italic> mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis</article-title><source><italic>The Lancet Oncology</italic></source><year>2010</year><volume>11</volume><issue>8</issue><fpage>753</fpage><lpage>762</lpage><pub-id pub-id-type="other">2-s2.0-77955277111</pub-id><pub-id pub-id-type="pmid">20619739</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Martini</surname><given-names>M</given-names></name><name><surname>Molinari</surname><given-names>F</given-names></name><etal/></person-group><article-title>Wild-type <italic>BRAF</italic> is required for response to panitumumab or cetuximab in metastatic colorectal cancer</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2008</year><volume>26</volume><issue>35</issue><fpage>5705</fpage><lpage>5712</lpage><pub-id pub-id-type="other">2-s2.0-57449095367</pub-id><pub-id pub-id-type="pmid">19001320</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagaert</surname><given-names>X</given-names></name></person-group><article-title>Prognostic biomarkers in colorectal cancer: where do we stand?</article-title><source><italic>Virchows Archiv</italic></source><year>2014</year><volume>464</volume><issue>3</issue><fpage>379</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">24487787</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benvenuti</surname><given-names>S</given-names></name><name><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><name><surname>di Nicolantonio</surname><given-names>F</given-names></name><etal/></person-group><article-title>Oncogenic activation of the <italic>RAS/RAF</italic> signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies</article-title><source><italic>Cancer Research</italic></source><year>2007</year><volume>67</volume><issue>6</issue><fpage>2643</fpage><lpage>2648</lpage><pub-id pub-id-type="other">2-s2.0-34047248571</pub-id><pub-id pub-id-type="pmid">17363584</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herreros-Villanueva</surname><given-names>M</given-names></name><name><surname>Gomez-Manero</surname><given-names>N</given-names></name><name><surname>Mu&#x000f1;iz</surname><given-names>P</given-names></name><name><surname>Garc&#x000ed;a-Gir&#x000f3;n</surname><given-names>C</given-names></name><name><surname>Coma del Corral</surname><given-names>MJ</given-names></name></person-group><article-title>
<italic>PIK3CA</italic> mutations in <italic>KRAS</italic> and <italic>BRAF</italic> wild type colorectal cancer patients. A study of Spanish population</article-title><source><italic>Molecular Biology Reports</italic></source><year>2011</year><volume>38</volume><issue>2</issue><fpage>1347</fpage><lpage>1351</lpage><pub-id pub-id-type="other">2-s2.0-79951579573</pub-id><pub-id pub-id-type="pmid">20571907</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tol</surname><given-names>J</given-names></name><name><surname>Koopman</surname><given-names>M</given-names></name><name><surname>Cats</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2009</year><volume>360</volume><issue>6</issue><fpage>563</fpage><lpage>572</lpage><pub-id pub-id-type="other">2-s2.0-59749091477</pub-id><pub-id pub-id-type="pmid">19196673</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study</article-title><source><italic>Annals of Oncology</italic></source><year>2011</year><volume>22</volume><issue>7</issue><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="other">2-s2.0-79956310674</pub-id><pub-id pub-id-type="pmid">21228335</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saridaki</surname><given-names>Z</given-names></name><name><surname>Tzardi</surname><given-names>M</given-names></name><name><surname>Sfakianaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>
<italic>BRAF</italic>V600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome</article-title><source><italic>PLoS ONE</italic></source><year>2013</year><volume>8</volume><pub-id pub-id-type="publisher-id">e84604</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downward</surname><given-names>J</given-names></name></person-group><article-title>Targeting RAS signalling pathways in cancer therapy</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2003</year><volume>3</volume><issue>1</issue><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="other">2-s2.0-0037264633</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Velho</surname><given-names>S</given-names></name><name><surname>Vakiani</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression</article-title><source><italic>Cancer Discovery</italic></source><year>2013</year><volume>3</volume><issue>3</issue><fpage>294</fpage><lpage>307</lpage><pub-id pub-id-type="other">2-s2.0-84876064070</pub-id><pub-id pub-id-type="pmid">23274911</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><etal/></person-group><article-title>Effectors of epidermal growth factor receptor pathway: the genetic profiling of <italic>KRAS</italic>, <italic>BRAF</italic>, <italic>PIK3CA</italic>, <italic>NRAS</italic> mutations in colorectal cancer characteristics and personalized medicine</article-title><source><italic>PLoS ONE</italic></source><year>2013</year><volume>8</volume><issue>12</issue><pub-id pub-id-type="publisher-id">e81628</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>AL</given-names></name><name><surname>Borger</surname><given-names>DR</given-names></name><name><surname>Szymonifka</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mutational analysis and clinical correlation of metastatic colorectal cancer</article-title><source><italic>Cancer</italic></source><year>2014</year><volume>120</volume><issue>10</issue><fpage>1482</fpage><lpage>1490</lpage><pub-id pub-id-type="pmid">24500602</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>di Bartolomeo</surname><given-names>M</given-names></name><name><surname>Pietrantonio</surname><given-names>F</given-names></name><name><surname>Perrone</surname><given-names>F</given-names></name><etal/></person-group><article-title>Lack of <italic>KRAS</italic>, <italic>NRAS</italic>, <italic>BRAF</italic> and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT</article-title><source><italic>Targeted Oncology</italic></source><year>2013</year><pub-id pub-id-type="other">2-s2.0-84879493704</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Oliner</surname><given-names>KS</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><etal/></person-group><article-title>Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2013</year><volume>369</volume><issue>11</issue><fpage>1023</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">24024839</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sclafani</surname><given-names>F</given-names></name><name><surname>Gonzalez</surname><given-names>D</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><etal/></person-group><article-title>RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial</article-title><source><italic>European Journal of Cancer</italic></source><year>2014</year><volume>50</volume><issue>8</issue><fpage>1430</fpage><lpage>1436</lpage><pub-id pub-id-type="pmid">24582914</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>F</given-names></name><name><surname>Lampis</surname><given-names>A</given-names></name><name><surname>Orsenigo</surname><given-names>M</given-names></name><etal/></person-group><article-title>
<italic>PI3KCA</italic>/<italic>PTEN</italic> deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients</article-title><source><italic>Annals of Oncology</italic></source><year>2009</year><volume>20</volume><issue>1</issue><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="other">2-s2.0-59049089201</pub-id><pub-id pub-id-type="pmid">18669866</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nosho</surname><given-names>K</given-names></name><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Ohnishi</surname><given-names>M</given-names></name><etal/></person-group><article-title>
<italic>PIK3CA</italic> mutation in colorectal cancer: relationship with genetic and epigenetic alterations</article-title><source><italic>Neoplasia</italic></source><year>2008</year><volume>10</volume><issue>6</issue><fpage>534</fpage><lpage>541</lpage><pub-id pub-id-type="other">2-s2.0-44449133319</pub-id><pub-id pub-id-type="pmid">18516290</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prenen</surname><given-names>H</given-names></name><name><surname>de Schutter</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>B</given-names></name><etal/></person-group><article-title>
<italic>PIK3CA</italic> mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer</article-title><source><italic>Clinical Cancer Research</italic></source><year>2009</year><volume>15</volume><issue>9</issue><fpage>3184</fpage><lpage>3188</lpage><pub-id pub-id-type="other">2-s2.0-65649086786</pub-id><pub-id pub-id-type="pmid">19366826</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Roock</surname><given-names>W</given-names></name><name><surname>Claes</surname><given-names>B</given-names></name><name><surname>Bernasconi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of <italic>KRAS</italic>, <italic>BRAF</italic>, <italic>NRAS</italic>, and <italic>PIK3CA</italic> mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis</article-title><source><italic>The Lancet Oncology</italic></source><year>2010</year><volume>11</volume><issue>8</issue><fpage>753</fpage><lpage>762</lpage><pub-id pub-id-type="other">2-s2.0-77955277111</pub-id><pub-id pub-id-type="pmid">20619739</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><name><surname>Martini</surname><given-names>M</given-names></name><name><surname>Molinari</surname><given-names>F</given-names></name><etal/></person-group><article-title>
<italic>PIK3CA</italic> mutations in colorectal cancer are associated with clinical resistance to <italic>EGFR</italic>-targeted monoclonal antibodies</article-title><source><italic>Cancer Research</italic></source><year>2009</year><volume>69</volume><issue>5</issue><fpage>1851</fpage><lpage>1857</lpage><pub-id pub-id-type="other">2-s2.0-62449302407</pub-id><pub-id pub-id-type="pmid">19223544</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karapetis</surname><given-names>CS</given-names></name><name><surname>Jonker</surname><given-names>D</given-names></name><name><surname>Daneshmand</surname><given-names>M</given-names></name><etal/></person-group><article-title>
<italic>PIK3CA</italic>, <italic>BRAF</italic>, and <italic>PTEN</italic> status and benefit from cetuximab in the treatment of advanced colorectal cancer&#x02014;results from NCIC CTG/AGITG CO.17</article-title><source><italic>Clinical Cancer Research</italic></source><year>2014</year><volume>20</volume><issue>3</issue><fpage>744</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">24218517</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z-Y</given-names></name><name><surname>Wu</surname><given-names>X-Y</given-names></name><name><surname>Huang</surname><given-names>Y-F</given-names></name><etal/></person-group><article-title>Promising biomarkers for predicting the outcomes of patients with <italic>KRAS</italic> wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis</article-title><source><italic>International Journal of Cancer</italic></source><year>2013</year><volume>133</volume><issue>8</issue><fpage>1914</fpage><lpage>1925</lpage><pub-id pub-id-type="other">2-s2.0-84881543270</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cully</surname><given-names>M</given-names></name><name><surname>You</surname><given-names>H</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><article-title>Beyond <italic>PTEN</italic> mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2006</year><volume>6</volume><issue>3</issue><fpage>184</fpage><lpage>192</lpage><pub-id pub-id-type="other">2-s2.0-33644513730</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>di Cristofano</surname><given-names>A</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name></person-group><article-title>The multiple roles of <italic>PTEN</italic> in tumor suppression</article-title><source><italic>Cell</italic></source><year>2000</year><volume>100</volume><issue>4</issue><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="other">2-s2.0-0034681264</pub-id><pub-id pub-id-type="pmid">10693755</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><name><surname>di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Nichelatti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multi-determinants analysis of molecular alterations for predicting clinical benefit to <italic>EGFR</italic>-targeted monoclonal antibodies in colorectal cancer</article-title><source><italic>PLoS ONE</italic></source><year>2009</year><volume>4</volume><issue>10</issue><pub-id pub-id-type="other">2-s2.0-70350028742</pub-id><pub-id pub-id-type="publisher-id">e7287</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jhawer</surname><given-names>M</given-names></name><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>
<italic>PIK3CA</italic> mutation/<italic>PTEN</italic> expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab</article-title><source><italic>Cancer Research</italic></source><year>2008</year><volume>68</volume><issue>6</issue><fpage>1953</fpage><lpage>1961</lpage><pub-id pub-id-type="pmid">18339877</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frattini</surname><given-names>M</given-names></name><name><surname>Saletti</surname><given-names>P</given-names></name><name><surname>Romagnani</surname><given-names>E</given-names></name><etal/></person-group><article-title>
<italic>PTEN</italic> loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients</article-title><source><italic>British Journal of Cancer</italic></source><year>2007</year><volume>97</volume><issue>8</issue><fpage>1139</fpage><lpage>1145</lpage><pub-id pub-id-type="other">2-s2.0-35348908314</pub-id><pub-id pub-id-type="pmid">17940504</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loupakis</surname><given-names>F</given-names></name><name><surname>Pollina</surname><given-names>L</given-names></name><name><surname>Stasi</surname><given-names>I</given-names></name><etal/></person-group><article-title>
<italic>PTEN</italic> expression and <italic>KRAS</italic> mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2009</year><volume>27</volume><issue>16</issue><fpage>2622</fpage><lpage>2629</lpage><pub-id pub-id-type="other">2-s2.0-66849140563</pub-id><pub-id pub-id-type="pmid">19398573</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razis</surname><given-names>E</given-names></name><name><surname>Briasoulis</surname><given-names>E</given-names></name><name><surname>Vrettou</surname><given-names>E</given-names></name><etal/></person-group><article-title>Potential value of <italic>PTEN</italic> in predicting cetuximab response in colorectal cancer: an exploratory study</article-title><source><italic>BMC Cancer</italic></source><year>2008</year><volume>8, article 234</volume><pub-id pub-id-type="other">2-s2.0-51249089269</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappuzzo</surname><given-names>F</given-names></name><name><surname>Magrini</surname><given-names>E</given-names></name><name><surname>Ceresoli</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>2004</year><volume>96</volume><issue>15</issue><fpage>1133</fpage><lpage>1141</lpage><pub-id pub-id-type="other">2-s2.0-4444332925</pub-id><pub-id pub-id-type="pmid">15292385</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scartozzi</surname><given-names>M</given-names></name><name><surname>Giampieri</surname><given-names>R</given-names></name><name><surname>Maccaroni</surname><given-names>E</given-names></name><etal/></person-group><article-title>Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab</article-title><source><italic>Journal of Translational Medicine</italic></source><year>2012</year><volume>10</volume><issue>1, article 71</issue><pub-id pub-id-type="other">2-s2.0-84862235601</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>DL</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Kruser</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members</article-title><source><italic>Oncogene</italic></source><year>2008</year><volume>27</volume><issue>28</issue><fpage>3944</fpage><lpage>3956</lpage><pub-id pub-id-type="other">2-s2.0-46249087766</pub-id><pub-id pub-id-type="pmid">18297114</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Corso</surname><given-names>S</given-names></name><name><surname>Bertotti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Amplification of the MET receptor drives resistance to anti-<italic>EGFR</italic> therapies in colorectal cancer</article-title><source><italic>Cancer Discovery</italic></source><year>2013</year><volume>3</volume><issue>6</issue><fpage>658</fpage><lpage>673</lpage><pub-id pub-id-type="other">2-s2.0-84878862323</pub-id><pub-id pub-id-type="pmid">23729478</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>V</given-names></name><name><surname>Landi</surname><given-names>L</given-names></name><name><surname>Molinari</surname><given-names>F</given-names></name><etal/></person-group><article-title>
<italic>HER2</italic> gene copy number status may influence clinical efficacy to anti-<italic>EGFR</italic> monoclonal antibodies in metastatic colorectal cancer patients</article-title><source><italic>British Journal of Cancer</italic></source><year>2013</year><volume>108</volume><issue>3</issue><fpage>668</fpage><lpage>675</lpage><pub-id pub-id-type="other">2-s2.0-84875217382</pub-id><pub-id pub-id-type="pmid">23348520</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinson</surname><given-names>DA</given-names></name><name><surname>Hochster</surname><given-names>HS</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients</article-title><source><italic>Investigational New Drugs</italic></source><year>2014</year><volume>32</volume><issue>1</issue><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="other">2-s2.0-84875871030</pub-id><pub-id pub-id-type="pmid">23568716</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNAs: target recognition and regulatory functions</article-title><source><italic>Cell</italic></source><year>2009</year><volume>136</volume><issue>2</issue><fpage>215</fpage><lpage>233</lpage><pub-id pub-id-type="other">2-s2.0-58249088751</pub-id><pub-id pub-id-type="pmid">19167326</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raisch</surname><given-names>J</given-names></name><name><surname>Darfeuille-Michaud</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name></person-group><article-title>Role of microRNAs in the immune system, inflammation and cancer</article-title><source><italic>World Journal of Gastroenterology</italic></source><year>2013</year><volume>19</volume><issue>20</issue><fpage>2985</fpage><lpage>2996</lpage><pub-id pub-id-type="pmid">23716978</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappuzzo</surname><given-names>F</given-names></name><name><surname>Sacconi</surname><given-names>A</given-names></name><name><surname>Landi</surname><given-names>L</given-names></name><etal/></person-group><article-title>MicroRNA signature in metastatic colorectal cancer patients treated with anti-<italic>EGFR</italic> monoclonal antibodies</article-title><source><italic>Clinical Colorectal Cancer</italic></source><year>2014</year><volume>13</volume><issue>1</issue><fpage>37</fpage><lpage>45.e4</lpage><pub-id pub-id-type="pmid">24503111</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragusa</surname><given-names>M</given-names></name><name><surname>Majorana</surname><given-names>A</given-names></name><name><surname>Statello</surname><given-names>L</given-names></name><etal/></person-group><article-title>Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment</article-title><source><italic>Molecular Cancer Therapeutics</italic></source><year>2010</year><volume>9</volume><issue>12</issue><fpage>3396</fpage><lpage>3409</lpage><pub-id pub-id-type="other">2-s2.0-78650505164</pub-id><pub-id pub-id-type="pmid">20881268</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruzzo</surname><given-names>A</given-names></name><name><surname>Graziano</surname><given-names>F</given-names></name><name><surname>Vincenzi</surname><given-names>B</given-names></name><etal/></person-group><article-title>High let-7a microRNA levels in <italic>KRAS</italic>-mutated colorectal carcinomas may rescue anti-<italic>EGFR</italic> therapy effects in patients with chemotherapy-refractory metastatic disease</article-title><source><italic>The Oncologist</italic></source><year>2012</year><volume>17</volume><issue>6</issue><fpage>823</fpage><lpage>829</lpage><pub-id pub-id-type="other">2-s2.0-84862877840</pub-id><pub-id pub-id-type="pmid">22584434</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Winder</surname><given-names>T</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A let-7 microRNA-binding site polymorphism in 3&#x02032;-untranslated region of <italic>KRAS</italic> gene predicts response in wild-type <italic>KRAS</italic> patients with metastatic colorectal cancer treated with cetuximab monotherapy</article-title><source><italic>Annals of Oncology</italic></source><year>2011</year><volume>22</volume><issue>1</issue><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="other">2-s2.0-78650321266</pub-id><pub-id pub-id-type="pmid">20603437</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebio</surname><given-names>A</given-names></name><name><surname>Par&#x000e9;</surname><given-names>L</given-names></name><name><surname>P&#x000e1;ez</surname><given-names>D</given-names></name><etal/></person-group><article-title>The LCS6 polymorphism in the binding site of let-7 microRNA to the <italic>KRAS</italic> 3&#x02032;-untranslated region: its role in the efficacy of anti-<italic>EGFR</italic>-based therapy in metastatic colorectal cancer patients</article-title><source><italic>Pharmacogenetics and Genomics</italic></source><year>2013</year><volume>23</volume><issue>3</issue><fpage>142</fpage><lpage>147</lpage><pub-id pub-id-type="other">2-s2.0-84873412791</pub-id><pub-id pub-id-type="pmid">23324806</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichler</surname><given-names>M</given-names></name><name><surname>Ress</surname><given-names>AL</given-names></name><name><surname>Winter</surname><given-names>E</given-names></name><etal/></person-group><article-title>MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients</article-title><source><italic>British Journal of Cancer</italic></source><year>2014</year><volume>110</volume><issue>6</issue><fpage>1614</fpage><lpage>1621</lpage><pub-id pub-id-type="pmid">24504363</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichler</surname><given-names>M</given-names></name><name><surname>Winter</surname><given-names>E</given-names></name><name><surname>Ress</surname><given-names>AL</given-names></name><etal/></person-group><article-title>miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with <italic>EGFR</italic> inhibitor</article-title><source><italic>Journal of Clinical Pathology</italic></source><year>2013</year><volume>67</volume><issue>3</issue><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">24098024</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubin</surname><given-names>F</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Burkes</surname><given-names>R</given-names></name><etal/></person-group><article-title>Canadian expert group consensus recommendations: <italic>KRAS</italic> testing in colorectal cancer</article-title><source><italic>Current Oncology</italic></source><year>2011</year><volume>18</volume><issue>4</issue><fpage>e180</fpage><lpage>e184</lpage><pub-id pub-id-type="other">2-s2.0-80051535563</pub-id><pub-id pub-id-type="pmid">21874108</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><collab>Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group</collab><article-title>Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in <italic>EGFR</italic> pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-<italic>EGFR</italic> therapy?</article-title><source><italic>Genetics in Medicine</italic></source><year>2013</year><volume>15</volume><issue>7</issue><fpage>517</fpage><lpage>527</lpage><pub-id pub-id-type="other">2-s2.0-84880544985</pub-id><pub-id pub-id-type="pmid">23429431</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therkildsen</surname><given-names>C</given-names></name><name><surname>Bergmann</surname><given-names>TK</given-names></name><name><surname>Henrichsen-Schnack</surname><given-names>T</given-names></name><name><surname>Ladelund</surname><given-names>S</given-names></name><name><surname>Nilbert</surname><given-names>M</given-names></name></person-group><article-title>The predictive value of <italic>KRAS</italic>, <italic>NRAS</italic>, <italic>BRAF</italic>, <italic>PIK3CA</italic> and <italic>PTEN</italic> for anti-<italic>EGFR</italic> treatment in metastatic colorectal cancer: a systematic review and meta-analysis</article-title><source><italic>Acta Oncologica</italic></source><year>2014</year></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Downstream signaling proteins of EGFR: (a) KRAS, (b) NRAS, (c) BRAF, and (d) PIK3CA. The most frequent activating mutation sites are shown as red spheres.</p></caption><graphic xlink:href="BMRI2014-591867.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Signaling pathways implicated in the lack of response to anti-EGFR therapies. &#x02217; indicates some receptors or downstream effectors which are responsible for anti-EGFR resistance when they are mutated or overexpressed.</p></caption><graphic xlink:href="BMRI2014-591867.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>A panel of different genes will be a step forward in the &#x0201c;personalized medicine&#x0201d; of CRC patients for selecting patients and predicting efficacy of anti-EGFR therapy.<italic> KRAS</italic> WT: no mutations were detected in exons 2, 3, and 4.</p></caption><graphic xlink:href="BMRI2014-591867.003"/></fig></floats-group></article>